A Phase IIb trial of Exendin 9-39 for Post-Bariatric Hypoglycemia (PBH)

Trial Profile

A Phase IIb trial of Exendin 9-39 for Post-Bariatric Hypoglycemia (PBH)

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Exendin 9 (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 New trial record
    • 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, completed trial data (see profile 266884) will trigger initiation of this trial planned in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top